...
首页> 外文期刊>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research >Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
【24h】

Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.

机译:伊班膦酸可预防男性心脏移植患者的骨质流失并降低椎骨骨折的风险:一项随机双盲,安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

Bone loss and fractures are common complications after cardiac transplantation (CTP). The aim of this study was to investigate whether intravenous ibandronate is an effective preventive option. Thirty-five male cardiac transplant recipients received either ibandronate (IBN) 2 mg intravenously every 3 mo or matching placebo (CTR) in addition to 500 mg calcium carbonate and 400 IE vitamin D(3). Sera were collected at CTP and every 3 mo thereafter. At baseline and 6 and 12 mo, standardized spinal X-rays and BMD measurements were taken. Bone biopsies were taken at CTP and after 6 mo from six patients. In the IBN group, 13% of the patients sustained a new morphometric vertebral fracture compared with 53% in the CTR group (absolute risk reduction [ARR], 40%; relative risk reduction [RRR], 75%; p = 0.04). BMD remained unchanged with IBN treatment but in the CTR group decreased at the lumbar spine by 25% and at the femoral neck by 23% (both p < 0.0001) over the 1-yr period. Serum bone resorption markers carboxy-terminal telopeptide region of type I collagen (sCTX) and TRACP 5b were significantly increased in the CTR group and decreased in the IBN group at all time points compared with baseline. In contrast, both osteocalcin and bone-specific alkaline phosphatase levels showed, after a similar decrease over the first 3 mo in both groups, a marked rise in the CTR subjects and steadily declining levels in the IBN patients throughout the remainder of the study period. Three paired biopsies were available from each group. Despite the small sample size, a difference in the relative change of eroded surface (68% in the CTR versus -23% in the IBN group, p < 0.05) could be shown. Intravenous IBN reduced fractures, preserved bone mass, and prevented uncoupling of bone formation and resorption after CTP. The favorable effects on bone turnover were also supported by histomorphometric findings.
机译:骨丢失和骨折是心脏移植(CTP)后的常见并发症。这项研究的目的是调查静脉注射伊班膦酸是否是一种有效的预防选择。 35位男性心脏移植受者除了每500毫克碳酸钙和400 IE维生素D(3)外,每3个月静脉注射伊班膦酸(IBN)2毫克或匹配安慰剂(CTR)。在CTP收集血清,此后每3个月收集一次。在基线,6和12 mo时,进行标准化的脊柱X射线和BMD测量。在CTP以及6个月后的6个月后进行了骨活检。在IBN组中,有13%的患者患有新的椎体形态骨折,而在CTR组中则为53%(绝对风险降低[ARR]为40%;相对风险降低[RRR]为75%; p = 0.04)。在IBN治疗期间,BMD保持不变,但在1年期间,CTR组的腰椎和股骨颈的BMD降低了25%(均p <0.0001)。与基线相比,CTR组的血清骨吸收标志物I型胶原蛋白的羧基末端端肽区域(sCTX)和TRACP 5b在所有时间点均显着增加,而IBN组则降低。相比之下,两组中的骨钙素和骨特异性碱性磷酸酶水平都显示出下降趋势,在两组的前3个月都有类似的下降之后,在整个研究期间的其余时间内,CTR受试者的CTR受试者明显升高,而IBN患者的水平却持续下降。每组可提供三对活检。尽管样本量很小,但可以显示出被腐蚀表面的相对变化(CTR中为68%,IBN组为-23%,p <0.05)。静脉IBN减少了骨折,保留了骨质,并防止了CTP后骨形成与吸收的解耦。组织形态计量学发现也支持对骨转换的有利作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号